title: Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS).
abstract: The prognosis of patients with de novo myelodysplastic syndrome (MDS) who are red blood cell transfusion-dependent (TD) and receive supportive care is inferior to that of patients who do not require transfusions. Whether TD also affects outcome after allogeneic transplantation is unknown. Consequently, in 172 de novo MDS patients (median age, 51 years), we analyzed the impact of TD on outcome after high-dose conditioning and allogeneic peripheral blood stem cell transplantation (PBSCT). With a median follow-up of 37 months, the probability of 3-year overall survival (OS) did not differ significantly between patients who were TD and those who were not TD before PBSCT (P=.1); however, transfusion burden, as reflected by ferritin levels, was correlated with a greater probability of severe acute graft-versus-host disease (aGVHD; P=.03) and a higher comorbidity index (P=.01), and OS was inferior in those patients with a ferritin level>1000 microg/L before PBSCT (P=.03). In multivariate analysis, only marrow myeloblast count (P=.01) and comorbidity index (P=.001) had a significant impact on OS. Our data do not identify TD as an independent negative prognostic factor for outcome after allogeneic PBSCT' however, iron overload (presumably transfusion-related) may contribute to poor transplantation success by adding to the overall comorbidities. Whether clinical intervention in the form of iron chelation can improve the outcome of allogeneic PBSCT in TD patients with MDS remains to be determined.
authors.affiliation: Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Dresden, Germany. Uwe.Platzbecker@uniklinikum-dresden.de
authors.forename: Uwe
authors.initials: U
authors.lastname: Platzbecker
authors.forename: Martin
authors.initials: M
authors.lastname: Bornhäuser
authors.forename: Ulrich
authors.initials: U
authors.lastname: Germing
authors.forename: Julian
authors.initials: J
authors.lastname: Stumpf
authors.forename: Bart L
authors.initials: BL
authors.lastname: Scott
authors.forename: Nicolaus
authors.initials: N
authors.lastname: Kröger
authors.forename: Rainer
authors.initials: R
authors.lastname: Schwerdtfeger
authors.forename: Alexandra
authors.initials: A
authors.lastname: Böhm
authors.forename: Guido
authors.initials: G
authors.lastname: Kobbe
authors.forename: Catrin
authors.initials: C
authors.lastname: Theuser
authors.forename: Werner
authors.initials: W
authors.lastname: Rabitsch
authors.forename: Peter
authors.initials: P
authors.lastname: Valent
authors.forename: Mohamed L
authors.initials: ML
authors.lastname: Sorror
authors.forename: Gerhard
authors.initials: G
authors.lastname: Ehninger
authors.forename: H Joachim
authors.initials: HJ
authors.lastname: Deeg
mesh_terms: D018572:Disease-Free Survival; D017707:Erythrocyte Transfusion; D005260:Female; D005293:Ferritins / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000401:mortality / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D015996:Survival Rate; D014184:Transplantation, Homologous
chemical_list: D005293:Ferritins